Myasthenia Gravis &
Restless Leg Syndrome
  Brian J. Piper, Ph.D., M.S.




                 October 22, 2012
Learning objectives
Pharmacy students should be able to:
1. Explain the involvement of antibodies against the
   neuromuscular junction to Myasthenia Gravis (MG)
   symptoms.
2. Describe the symptoms of Restless Leg Syndrome
   (RLS) and abnormalities in the dopamine system.
MG Overview
 • myasthenia: muscle weakness (skeletal)
 • gravis: lethal (historically)
 • chronic autoimmune

Sir Thomas Willis




  1621-1675
MG Symptoms
   • ptosis
   • diplopia
   • slurred speech, difficulty chewing and
     swallowing
   • weakness in the arms and legs
   • chronic muscle fatigue and difficulty breathing



Symptoms & Onset (0:07 to 1:07): http://www.youtube.com/watch?v=6W-mC_Lg4WU
Myasthenia Gravis Foundation of America: ww.myasthenia.org/
Epidemiology of MG
  • incidence: 20/100K (State: 266, City: 7)
  • onset: women: 20s, men 60s
  • sex ratio of 3:2




                         ------------------------------------------------------




Phillips, L. H. (2003). Annals of the New York Academy of Sciences, 998, 407-412.
MS Characteristics
• Antibodies for:
  – nicotinic acetylcholine receptor
  – muscle specific kinase (MuSK)
• ice-pack diagnostic test
Neuromuscular Junction




Neuromuscular Junction 0 to 1 min: http://www.youtube.com/watch?v=9FF6UKvDgeE
Antibodies Against nACh
 • Rabbits (N=7) received
   injections of acetylcholine
   receptor from electric eel
 • Paralysis (top) is reversed
   by increasing ACh (bottom)

   Electrophorus electricus




Patrick & Lindstrom (1973). Science, 180(4088 ), 871-872.
Nicotinic Acetylcholine (nACh)
                  Receptor of Muscle




Drachman DB (1998). New England Journal of Medicine, 330, 1797-1810.
Measurement of nACh
• Deltoid biopsies from MG or
  non-MG (N=33/group)
• 125I α bungarotoxin




Pestronck et al. (1985). Muscle & Nerve, 8, 245-251.
Drachman DB (1998). New England Journal of Medicine, 330, 1797-1810.
Types of MG
• nACh receptor antibody + : 80%
  – ocular only MG
• MuSK antibody +
• antibody -
Lambert-Eaton Myasthenic Syndrome
•   symptoms: ptosis & diplopia
•   cranial nerve reflexes: absent
•   antibodies against calcium channels, ↓ACh
•   lung-cancer
Pattern & Spreading of Weakness




Verschuuren et al. (2010). Autoimmunity, 43(5-6), 344-352.
Non-Pharmacological Treatments
• plasmapheresis
• thymectomy
Plasmapheresis: An Evidence Based
                 Treatment?
• developed in 1976
• widely used and generally
  accepted by clinicians &
  patients
• “No adequate RCTs have been
  performed to determine whether
  plasma exchange improves the short-
  or long-term outcome for chronic
  myasthenia gravis” Cochrane
  Reviews, 2002/2011

                                                         Methodological rating summary.
Gajdos P. et al. (2011). Cochrane Review 2011 Issue 3.
Cortese et al. (2009). Neurology, 76, 294–300.
Plasmapheresis: An Evidence Based
                 Treatment?
•   widely used and generally accepted by clinicians & patients

•   “No adequate RCTs have been performed to determine whether plasma exchange improves the
    short- or long-term outcome for chronic myasthenia gravis” Cochrane Reviews, 2002/2011


•   “Because of the lack of randomized controlled studies with masked outcomes, there is
    insufficient evidence to support or refute the efficacy of plasmapheresis” American
    Academy of Neurology, 2009




Gajdos P. et al. (2011). Cochrane Review 2011 Issue 3.
Cortese et al. (2009). Neurology, 76, 294–300.
Thymectomy
 • 15% of MG have thymomas
 • 70% of MG have thymus hyperplasia
 • Controversial (non-thymoma) & varied results
      – younger > older
      – delayed response
      – unchanged (25%), improved (50%), remits (25%)




Raica et al. (2008). Clinical Experimental Medicine, 8, 61-64.
What causes MG?
•   unknown (majority)
•   penicillamine
•   maternal/neonatal
•   Candidates
    – virus: ?
    – genetics
Restless
    Leg
    Syndrome
       Sir Thomas Willis




          1621-1675



Allen et al. (2003). Sleep Medicine, 4, 101-119.
Epidemiology

    •   10% (2.7%)
    •   females > males
    •   Caucasians > African-Americans
    •   increases with age
    •   risk factors
        – Parkinson’s Disease
        – pregnancy (20%)
        – ADHD

Example symptoms (0 to 30 sec): http://www.youtube.com/watch?v=k2eGoHk9AAc
Dopaminergic Abnormalities (Subtle) & RLS

   • RLS or controls (N=13/group, age matched)
   • PET scanning for dopamine integrity (DOPA
     uptake) or D2 receptors (raclopride)




Positron Emission Tomography
1 positron + 1 electron = 2 gamma rays
Scatter diagram of individual caudate and putamen 18F-
   DOPA uptake in patients with RLS treated (□) and not
   treated (▪) with L-DOPA and in control subjects (•).




                                                           *
                             Controls      RLS       Controls   RLS
 * p < .05

Turjanski N et al. (1999). Neurology, 52, 932-932.
Scatter diagram of individual caudate and putamen D2
  binding in patients with RLS treated (□) and not treated (▪)
  with L-DOPA and in control subjects (•).




                                   *
                                                          *


                            Controls RLS              Controls RLS
   * p < .05

Turjanski N et al. (1999). Neurology , 52, 932-932.
Iron & RLS
  • Ferritin: iron storage protein
  • Spinal taps in controls, RLS FH+, or RLS FH-
    (N = 8/group) ->
  • Transferrin Receptor: protein needed for
    import of Fe into cell
  • Postmortem substantia nigra tissue stained
    for transferrin in:
      controls                           RLS




Early et al. (2000). Neurology, 54, 1698 – 1700; Conner et al. (2003). Neurology, 61, 304-309.
RLS & Catecholamine Biosynthesis
 • Tyrosine: non-essential amino
   acid found in
   eggs, peanuts, liver, turkey, salm
   on
 • Iron cofactor




TH: tyrosine hydroxylase, DOPA: dihydroxyphenylalanine
Limited Efficacy of Iron
                         Supplementation
                                                 • “There is insufficient evidence to
                                                   determine whether iron therapy is
                                                   beneficial for the treatment of
                                                   RLS.”
                                                 • Benefit identified in 1 study with
                                                   patients that were iron deficient.




Trotti et al. (2012). Cochrane Database Systemic Reviews, 5:CD007834.
More Info
• MG Quick Overview: 0:50 to 4:20 at:
  http://www.youtube.com/watch?v=j7ISC4OU--o
• RLS Pathophysiology at:
  http://www.youtube.com/watch?v=p7G803oDx-c

More Related Content

PPTX
R Shravani RCVS Grand Rounds final .ppt
PPT
03 01-06 approach to ataxia
PPTX
Moyamoya Angiopathy
PPTX
NEDA in multiple sclerosis
PPTX
Cortical dysplasia and epilepsy
PPTX
Approach to headache
PDF
"Личный бренд: диагностика и развитие". Мастер-класс для специалистов по прод...
PPTX
Metabolic headache
R Shravani RCVS Grand Rounds final .ppt
03 01-06 approach to ataxia
Moyamoya Angiopathy
NEDA in multiple sclerosis
Cortical dysplasia and epilepsy
Approach to headache
"Личный бренд: диагностика и развитие". Мастер-класс для специалистов по прод...
Metabolic headache

What's hot (20)

PPTX
Guillain barre syndrome (Short Lecture by Dr Aslam)
PPTX
Approach to chorea by dr srimant pattnaik
PPTX
A Review on Neurosarcoidosis Dec 21, 2016
PPTX
Dystonia
PPTX
Stiff Person Syndrome
PPT
Headache for post basic neuroscience course 2015
PPTX
Approach to Headache
PPTX
Parkinson's disease
PPTX
Brachial plexopathy
PPTX
Psp - Progressive Supranuclear Palsy
PPTX
Approach to a patient with headache
PPTX
Neurosarcoidosis
PPT
Insomnia Presentation
PDF
clinically isolated syndromes
PPTX
High frequency oscillations
PPT
MS diagnostic criteria
PPTX
myopthies.pptx
PPTX
Old vs New Antiseizure drugs.pptx
PPTX
Myasthenia gravis
PPT
Headache and associated emergencies
Guillain barre syndrome (Short Lecture by Dr Aslam)
Approach to chorea by dr srimant pattnaik
A Review on Neurosarcoidosis Dec 21, 2016
Dystonia
Stiff Person Syndrome
Headache for post basic neuroscience course 2015
Approach to Headache
Parkinson's disease
Brachial plexopathy
Psp - Progressive Supranuclear Palsy
Approach to a patient with headache
Neurosarcoidosis
Insomnia Presentation
clinically isolated syndromes
High frequency oscillations
MS diagnostic criteria
myopthies.pptx
Old vs New Antiseizure drugs.pptx
Myasthenia gravis
Headache and associated emergencies
Ad

Viewers also liked (20)

PPTX
Neuropharmacology: Affective Disorders
PPTX
Anticonvulsants Part II
PPTX
Pathophysiology: Neuroanatomy Part II
PPTX
Neuropharmacology: Anxiety Disorders
PPT
Neuropharmacology: Schizophrenia
PPTX
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
PPTX
Pathophysiology: Migraine & Headache
PPT
Myasthenia Gravis - Pathophysiology, Cl. Features, DD
PPTX
Restless leg syndrome in ckd
PPTX
Eliminate restless leg syndrome
PPT
Restless leg syndrome
PPTX
Restless legs syndrome
PPT
Lyme Disease Information
PPTX
Restless leg syndrome
PPTX
Restless Leg Syndrome
PDF
Respiratory failure
PPTX
04 non malignant lymphocyte disorders
PDF
Medical timelines sample
PDF
Points about medical topics sample
PDF
Neuropharmacology: Affective Disorders
Anticonvulsants Part II
Pathophysiology: Neuroanatomy Part II
Neuropharmacology: Anxiety Disorders
Neuropharmacology: Schizophrenia
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Pathophysiology: Migraine & Headache
Myasthenia Gravis - Pathophysiology, Cl. Features, DD
Restless leg syndrome in ckd
Eliminate restless leg syndrome
Restless leg syndrome
Restless legs syndrome
Lyme Disease Information
Restless leg syndrome
Restless Leg Syndrome
Respiratory failure
04 non malignant lymphocyte disorders
Medical timelines sample
Points about medical topics sample
Ad

Similar to Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome (20)

PPT
Tuberous Sclerosis - Orrin Devinsky, MD
PPT
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
PPTX
Testosterone Deficiency in Male by Dr Selim
PPTX
Connective Tissue Diseases
PDF
Dietary Administration of Diquat for 13 Weeks Does Not Result in a Loss of Do...
PPTX
Zwiegers Thesis Defense
PPTX
Nutritional and metabolic considerations in elderly dialysis patients
PPTX
Imaging in Acute Kidney Injury, how not to harm patients
PPT
2013 SOT_NAMPT_CFU_poster
PPTX
THE THYROID AXIS FROM "A" TO "Z"
PDF
Plenary presentation saturday 11 7_dr. lucie bruijn
PPTX
rPTH - 12 yrs therapy for hypoparathyroidism.pptx
PPTX
circadian rhythm in Spinal cord injuries
PPTX
Diaz-Arrastia, Ramon
PPTX
LHRH agonist vs antagonist in prostate cancer
PPTX
Osteoporosis by dr.arun
PDF
Dr. Boles MitoAction Presentation 9/13/13
PPTX
Hormones and Mental Health - Thyroid and Testosterone ptx
PDF
Neuropathological correlates imperial_college_4_sl_sh_2feb2018
PPT
Mechanism of protection by daily...
Tuberous Sclerosis - Orrin Devinsky, MD
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
Testosterone Deficiency in Male by Dr Selim
Connective Tissue Diseases
Dietary Administration of Diquat for 13 Weeks Does Not Result in a Loss of Do...
Zwiegers Thesis Defense
Nutritional and metabolic considerations in elderly dialysis patients
Imaging in Acute Kidney Injury, how not to harm patients
2013 SOT_NAMPT_CFU_poster
THE THYROID AXIS FROM "A" TO "Z"
Plenary presentation saturday 11 7_dr. lucie bruijn
rPTH - 12 yrs therapy for hypoparathyroidism.pptx
circadian rhythm in Spinal cord injuries
Diaz-Arrastia, Ramon
LHRH agonist vs antagonist in prostate cancer
Osteoporosis by dr.arun
Dr. Boles MitoAction Presentation 9/13/13
Hormones and Mental Health - Thyroid and Testosterone ptx
Neuropathological correlates imperial_college_4_sl_sh_2feb2018
Mechanism of protection by daily...

More from Brian Piper (20)

PPTX
Drug Abuse & Society (RX 462) Presentations-Spring 2014
PPTX
electronic cigarettes
PDF
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
PPTX
Drug abuse and society drug presentations: Spring 2013
PPTX
Sedative & Hypnotic Drugs Part II
PPTX
Sedative & Hypnotic Agents Part I
PPTX
Agents for Bipolar
PPTX
Psychopharmacology of Anxiety: Part II OCD & PTSD
PPTX
Psychopharmacology of Anxiety Disorders I: GAD & SAD
PPTX
Antipsychotics Part II
PPTX
Antipsychotics I
PPTX
Anti Inflammation agents for CNS
PPTX
Antidepressants Part II
PPTX
Antidepressants Part I
PPTX
Anticonvulsants Part I
PPTX
Agents for Brain Injury
PPTX
ADHD Drugs
PPTX
Pathophysiology: Alzheimer's Disease
PPTX
Pathophysiology: Introduction to Neuropsychiatry
PPTX
Pathophysiology: Neuroanatomy Part I
Drug Abuse & Society (RX 462) Presentations-Spring 2014
electronic cigarettes
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Drug abuse and society drug presentations: Spring 2013
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Agents Part I
Agents for Bipolar
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Antipsychotics Part II
Antipsychotics I
Anti Inflammation agents for CNS
Antidepressants Part II
Antidepressants Part I
Anticonvulsants Part I
Agents for Brain Injury
ADHD Drugs
Pathophysiology: Alzheimer's Disease
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Neuroanatomy Part I

Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome

  • 1. Myasthenia Gravis & Restless Leg Syndrome Brian J. Piper, Ph.D., M.S. October 22, 2012
  • 2. Learning objectives Pharmacy students should be able to: 1. Explain the involvement of antibodies against the neuromuscular junction to Myasthenia Gravis (MG) symptoms. 2. Describe the symptoms of Restless Leg Syndrome (RLS) and abnormalities in the dopamine system.
  • 3. MG Overview • myasthenia: muscle weakness (skeletal) • gravis: lethal (historically) • chronic autoimmune Sir Thomas Willis 1621-1675
  • 4. MG Symptoms • ptosis • diplopia • slurred speech, difficulty chewing and swallowing • weakness in the arms and legs • chronic muscle fatigue and difficulty breathing Symptoms & Onset (0:07 to 1:07): http://www.youtube.com/watch?v=6W-mC_Lg4WU Myasthenia Gravis Foundation of America: ww.myasthenia.org/
  • 5. Epidemiology of MG • incidence: 20/100K (State: 266, City: 7) • onset: women: 20s, men 60s • sex ratio of 3:2 ------------------------------------------------------ Phillips, L. H. (2003). Annals of the New York Academy of Sciences, 998, 407-412.
  • 6. MS Characteristics • Antibodies for: – nicotinic acetylcholine receptor – muscle specific kinase (MuSK) • ice-pack diagnostic test
  • 7. Neuromuscular Junction Neuromuscular Junction 0 to 1 min: http://www.youtube.com/watch?v=9FF6UKvDgeE
  • 8. Antibodies Against nACh • Rabbits (N=7) received injections of acetylcholine receptor from electric eel • Paralysis (top) is reversed by increasing ACh (bottom) Electrophorus electricus Patrick & Lindstrom (1973). Science, 180(4088 ), 871-872.
  • 9. Nicotinic Acetylcholine (nACh) Receptor of Muscle Drachman DB (1998). New England Journal of Medicine, 330, 1797-1810.
  • 10. Measurement of nACh • Deltoid biopsies from MG or non-MG (N=33/group) • 125I α bungarotoxin Pestronck et al. (1985). Muscle & Nerve, 8, 245-251.
  • 11. Drachman DB (1998). New England Journal of Medicine, 330, 1797-1810.
  • 12. Types of MG • nACh receptor antibody + : 80% – ocular only MG • MuSK antibody + • antibody -
  • 13. Lambert-Eaton Myasthenic Syndrome • symptoms: ptosis & diplopia • cranial nerve reflexes: absent • antibodies against calcium channels, ↓ACh • lung-cancer
  • 14. Pattern & Spreading of Weakness Verschuuren et al. (2010). Autoimmunity, 43(5-6), 344-352.
  • 16. Plasmapheresis: An Evidence Based Treatment? • developed in 1976 • widely used and generally accepted by clinicians & patients • “No adequate RCTs have been performed to determine whether plasma exchange improves the short- or long-term outcome for chronic myasthenia gravis” Cochrane Reviews, 2002/2011 Methodological rating summary. Gajdos P. et al. (2011). Cochrane Review 2011 Issue 3. Cortese et al. (2009). Neurology, 76, 294–300.
  • 17. Plasmapheresis: An Evidence Based Treatment? • widely used and generally accepted by clinicians & patients • “No adequate RCTs have been performed to determine whether plasma exchange improves the short- or long-term outcome for chronic myasthenia gravis” Cochrane Reviews, 2002/2011 • “Because of the lack of randomized controlled studies with masked outcomes, there is insufficient evidence to support or refute the efficacy of plasmapheresis” American Academy of Neurology, 2009 Gajdos P. et al. (2011). Cochrane Review 2011 Issue 3. Cortese et al. (2009). Neurology, 76, 294–300.
  • 18. Thymectomy • 15% of MG have thymomas • 70% of MG have thymus hyperplasia • Controversial (non-thymoma) & varied results – younger > older – delayed response – unchanged (25%), improved (50%), remits (25%) Raica et al. (2008). Clinical Experimental Medicine, 8, 61-64.
  • 19. What causes MG? • unknown (majority) • penicillamine • maternal/neonatal • Candidates – virus: ? – genetics
  • 20. Restless Leg Syndrome Sir Thomas Willis 1621-1675 Allen et al. (2003). Sleep Medicine, 4, 101-119.
  • 21. Epidemiology • 10% (2.7%) • females > males • Caucasians > African-Americans • increases with age • risk factors – Parkinson’s Disease – pregnancy (20%) – ADHD Example symptoms (0 to 30 sec): http://www.youtube.com/watch?v=k2eGoHk9AAc
  • 22. Dopaminergic Abnormalities (Subtle) & RLS • RLS or controls (N=13/group, age matched) • PET scanning for dopamine integrity (DOPA uptake) or D2 receptors (raclopride) Positron Emission Tomography 1 positron + 1 electron = 2 gamma rays
  • 23. Scatter diagram of individual caudate and putamen 18F- DOPA uptake in patients with RLS treated (□) and not treated (▪) with L-DOPA and in control subjects (•). * Controls RLS Controls RLS * p < .05 Turjanski N et al. (1999). Neurology, 52, 932-932.
  • 24. Scatter diagram of individual caudate and putamen D2 binding in patients with RLS treated (□) and not treated (▪) with L-DOPA and in control subjects (•). * * Controls RLS Controls RLS * p < .05 Turjanski N et al. (1999). Neurology , 52, 932-932.
  • 25. Iron & RLS • Ferritin: iron storage protein • Spinal taps in controls, RLS FH+, or RLS FH- (N = 8/group) -> • Transferrin Receptor: protein needed for import of Fe into cell • Postmortem substantia nigra tissue stained for transferrin in: controls RLS Early et al. (2000). Neurology, 54, 1698 – 1700; Conner et al. (2003). Neurology, 61, 304-309.
  • 26. RLS & Catecholamine Biosynthesis • Tyrosine: non-essential amino acid found in eggs, peanuts, liver, turkey, salm on • Iron cofactor TH: tyrosine hydroxylase, DOPA: dihydroxyphenylalanine
  • 27. Limited Efficacy of Iron Supplementation • “There is insufficient evidence to determine whether iron therapy is beneficial for the treatment of RLS.” • Benefit identified in 1 study with patients that were iron deficient. Trotti et al. (2012). Cochrane Database Systemic Reviews, 5:CD007834.
  • 28. More Info • MG Quick Overview: 0:50 to 4:20 at: http://www.youtube.com/watch?v=j7ISC4OU--o • RLS Pathophysiology at: http://www.youtube.com/watch?v=p7G803oDx-c

Editor's Notes

  • #2: Christopher Robin Milne, the son of A. A. Milne (author of Winnie-the-Pooh ) and the person on whom Christopher Robin was based, lived with myasthenia gravis for many years (1920-1996).
  • #4: The cardinal features are weakness and fatigability.See alsohttp://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm
  • #5: Ptosis or diplopia, are the initial symptom of myasthenia gravis in two-thirds of patients. The severity of weakness fluctuates during the day, usually being least severe in the morning and worse as the day progresses, especially after prolonged use of affected muscles.
  • #6: There are approximately 36,000 to 60,000 cases in the United States.2011 Maine population estimate: 1,328,188; Bangor: 35,473. The incidence of MG has been increasing over the past few decades due to better diagnosis. Also, better treatment has resulted in longer-survival.
  • #7: Symptoms typically not observed until 70% reduction in nACh receptors. Muscle Specific Kinase (MuSK) is a receptor tyrosine kinase.MuSK induces cellular signaling by causing the addition of phosphate molecules to particular tyrosines on itself, and on proteins that bind the cytoplasmic domain of the receptor. Knock-out mice lacking MuSK do not form functional neuromuscular junctions.  Activation of MuSK (by agrin) induce &quot;clustering&quot; of acetylcholine receptors.
  • #8: Decreased signaling is not just due to antibody binding.The underlying defect is a decrease in the number of available ACh receptors at neuromuscular junctions due to an antibody mediated autoimmune attack.
  • #9: The electric eel (Electrophorus electricus) is an electric fish found in South American capable of generating powerful electric shocks of up to 600 volts which it uses for hunting and self-defense. Paralysis was observed 3 weeks after receptor injections.
  • #10: Channel opening occurs when ACh binds to both alpha subunits. This lets cations enter. The majority of MG patients have antibodies against the alpha subunit and the main immunogenic region. Howere, the antibodies in MG patients are diverse and target different parts of the receptor.
  • #11: Of the controls, the majority did not have other neuromuscular disease. Alpha bungarotoxin is found in the venom of differetkraites (pronounced “crates”) that are found in SE Asia. Poisoning causes ptosis and diplopia.Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays because of its long half-life (59 days).
  • #12: There is endocytosis of the nACh receptor and morphological changes in the muscle.
  • #13: Most MG patients have generalized muscle effects but a subset have only ocular effects. Muscle Specific Kinase (MuSK) is a receptor tyrosine kinase.MuSK induces cellular signaling by causing the addition of phosphate molecules to particular tyrosines on itself, and on proteins that bind the cytoplasmic domain of the receptor. Knock-out mice lacking MuSK do not form functional neuromuscular junctions.
  • #14: Reduced or absent reflexes occur with LEM but not generalized MG. Antibodies against P/Q calcium channels results in reduced acetylcholine release. Three quarters of people with LEMS also have disruption of the autonomic nervous system. This may be experienced as a dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension (falls in blood pressure on standing, potentially leading to blackouts).Chest X-ray showing a tumor in the left lung (right side of the image). LEMS have difficulties with lower-extremities and may notice difficulties climbing stairs.
  • #15: The type of Myasthenia have different patterns of weakness. AChR is more localized to the eyes. There is more impairment in the tongue, pharnx, and larnx (the medulla or bulbar type) with MuSK and the lower extremities in LEMS.
  • #16: Plasmapheresis consists of taking blood from one vein, separating plasma from blood cells using membrane filtration or centrifugation and then returning blood with a plasma substitute into another vein. An alternative method of removing antibodies is immunoabsorption. In this the plasma is passed down an absorbant column, which removes antibodies, and then returned to the patient.
  • #17: Rabies vaccine example. There have been 4 RCTs (total patients = 128) and 3 were non-blind!
  • #19: Thymoma (thī-mō&apos;mə) is a usually benign tumor of the thymus. Thymectomy has been used for MG since the 1940s. Patients over 50 are less likely to benefit. Some improvement may be seen 6-12 months post-surgery.
  • #20: Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritisand is also a metabolite of penicillin. It also  increases urinary copper excretion by chelation [kee-ley-shuhn]. It causes MG but muscle weakness is typically mild and it typically resolves after a couple weeks.
  • #21: Sir Thomas Willis (1672):Wherefore to some, when being abed they betake themselves to sleep, presently in the arms and legs, leapings and contractions on the tendons, and so great a restlessness and tossings of other members ensue, that the diseased are no more able to sleep, than if they were in a place of the greatest torture.More recent patient terms for the sensation includes:“soda bubbling in veins”, “the gotta moves”, “crazy legs”, “itching bones”, “shock-like feelings”, and “worms moving”.
  • #22: 10% of general U.S. population has symptoms of RLS with daily or severe symptoms in about one-quarter.
  • #23: PET ­produces images of the body by detecting the radiation emitted from radioactive substances. These substances are injected into the body, and are usually tagged with a radioactive atom, such as Carbon-11, Fluorine-18, Oxygen-15, or Nitrogen-13.PET detects the gamma rays given off at the site where a positron emitted from the radioactive substance collides with an electron in the tissue. See also http://www.howstuffworks.com/nuclear-medicine1.htmRaclopride is a synthetic compound that acts as an antagonist on D2 dopamine receptors.
  • #26: A small study (N=12 RLS, half family history positive) showed a reduction in cerebrospinal fluid ferritin (an index of brain ferritin).Transferrin receptor (TfR) is a carrier protein for transferrin. It is needed for the import of iron into the cell.Transferrin receptor immunoreaction product (blue) is present on most of the brown neuromelanin containing cells in the control brains. The immunoreaction product is found on the soma and extends into a primary process in all cases (e.g., cell at arrow). In the RLS brains, the immunoreaction product for Tf receptor is minimal and immunostained cell processes are rare on the brown neuromelanin cells (e.g., cell at arrow).
  • #27: Overall, abnormalities in the cofactor for DOPA synthesis, DOPA uptake, and in dopamine receptor levels have been identified in RLSA cofactor is a non-protein chemical compound that is bound to a protein and is required for the protein&apos;s biological activity. Cofactors are &quot;helper molecules&quot; that assist in biochemical transformations.
  • #28: 6 trials of Fe (oral or iv) for RLS (N=197) which used different criteria for defining RLS and endpoints. Results for the 4 that used International RLS criteria produced variable results.Current guideline for RLS by the RLS Foundation’s Medical Foundation advisory board recommend iron therapy for patients was a low ferritin (usually less than 20ng/ml) and consideration of iron therapy on a case by case basis, with ferritin levels below 50ng/ml.